speb/financial-data huggingface dataset:
Financial ratios for ITCHOTELS.NS — annual report dated 2025-03-31
Total revenue: 412188449.8480243
Gross profit: 272740238.4849193
Operating income: 99559270.51671731
Net income: 74542903.90460603
Capital expenditures: 44632920.27121814
Operating cash flow: 93647416.41337386
Depreciation & amortization: 47145195.23030161
Net tangible assets: 1246091886.8365676
Owner earnings: 77055178.86368948
Return on net tangible assets (%): 6.183747737842043
Capex to operating income (%): 44.83050150887123
Buffett classification: The Good
Stock price: 2.2898821332710937
P/E ratio: 63.98691202196837
Shares outstanding: 2082976309
Book value: 1254201543.1377132
P/B ratio: 3.803033300432115
Market cap (USD): 4769770234.006069
Debt to equity: 0.006832307399771076
Current ratio: 2.9782380205730825
Quick ratio: 1.9089546323896824
Effective tax rate (%): 27.87367373255209
Interest coverage ratio: 128.25753012048193
COGS to revenue (%): 33.83117877624182
SG&A to revenue (%): 6.108580601612089
Free cash flow (dilution-adjusted): 48515314.47276128
Buyback yield (%): 0
Retained earnings: 33542202.47837269
Inventory turnover: 0.9610686776886139
Receivables turnover: 17.474649353223967
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 7.526211786996974
FCF margin (%): 11.770178055850204
Rule of 40 score: 11.770178055850204
Financial ratios for ITCHOTELS.NS — quarterly report dated 2025-03-31
Total revenue: 123011456.6284779
Gross profit: 90678045.35889642
Operating income: 36531447.27612813
Net income: 30143792.377834927
Capital expenditures: 0
Depreciation & amortization: 11667056.347907411
Net tangible assets: 1246091886.8365676
Owner earnings: 41810848.72574234
Return on net tangible assets (%): 3.355358394306445
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 2.2898821332710937
P/E ratio: 39.55847836114788
Shares outstanding: 2082976309
Book value: 1254201543.1377132
P/B ratio: 3.803033300432115
Market cap (USD): 4769770234.006069
Debt to equity: 0.006832307399771076
Current ratio: 2.9782380205730825
Quick ratio: 1.9089546323896824
Effective tax rate (%): 27.06211812627291
Interest coverage ratio: 186.0059523809524
COGS to revenue (%): 26.28487797460655
Buyback yield (%): 0
Retained earnings: 33542202.47837269
Inventory turnover: 0.22283992394211868
Receivables turnover: 5.215046835505774
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 2.76160529962388
Rule of 40 score: 0
Financial ratios for ITCHOTELS.NS — quarterly report dated 2025-06-30
Total revenue: 94655979.40556987
Gross profit: 62879709.80575708
Operating income: 16642873.859115377
Net income: 15645916.218113739
Capital expenditures: 0
Depreciation & amortization: 11986894.45354552
Owner earnings: 27632810.67165926
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 2.58530306576176
P/E ratio: 86.04681506814374
Shares outstanding: 2082976309
Market cap (USD): 5385125037.566815
Effective tax rate (%): 29.17902542372881
Interest coverage ratio: 85.68072289156626
COGS to revenue (%): 33.57027184057953
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -23.051086459814808
Rule of 40 score: -23.051086459814808
Financial ratios for ITCHOTELS.NS — quarterly report dated 2025-09-30
Total revenue: 93803833.14543405
Gross profit: 63014656.14430665
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 2.5455467869222095
P/E ratio: 74.71470776665349
Shares outstanding: 2082976309
Market cap (USD): 5302313650.610033
COGS to revenue (%): 32.822941204749775
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -0.9002561333020992
Rule of 40 score: -0.9002561333020992
Financial ratios for ITCHOTELS.NS — quarterly report dated 2025-12-31
Total revenue: 136378522.8918347
Gross profit: 101657569.3438788
Operating income: 40419962.12543166
Net income: 26381864.765511867
Capital expenditures: 0
Depreciation & amortization: 11608555.196613569
Owner earnings: 37990419.962125435
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 2.1849170101370166
P/E ratio: 63.0598746469453
Shares outstanding: 2082976309
Market cap (USD): 4551130369.246518
Effective tax rate (%): 27.603704949102802
Interest coverage ratio: 165.6849315068493
COGS to revenue (%): 25.459253269295168
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 45.38694029741043
Rule of 40 score: 45.38694029741043
Financial ratios for IXI.L — annual report dated 2021-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 0.010810810810810811
Shares outstanding: 218974282
Market cap (USD): 2367289.535135135
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IXI.L — annual report dated 2022-09-30
Total revenue: 9603333.333333334
Gross profit: 5825555.555555555
Operating income: 1008888.8888888889
Net income: 1146666.6666666667
Capital expenditures: 207777.77777777778
Operating cash flow: 1582222.2222222222
Depreciation & amortization: 710000
Net tangible assets: 8784444.444444444
Owner earnings: 1648888.888888889
Return on net tangible assets (%): 18.770554009612955
Capex to operating income (%): 20.59471365638767
Buffett classification: The Great
Stock price: 0.003777777777777778
P/E ratio: 0.7214268980620154
Shares outstanding: 218974282
Book value: 13881111.11111111
P/B ratio: 0.059594377555431045
Market cap (USD): 827236.1764444445
Debt to equity: 0.0413031297526615
Current ratio: 5.331988472622478
Quick ratio: 5.331988472622478
Effective tax rate (%): -16.610169491525426
Interest coverage ratio: 27.515151515151516
COGS to revenue (%): 39.338192757144505
R&D to revenue (%): 14.080758995719078
SG&A to revenue (%): 44.047205831308574
Free cash flow (dilution-adjusted): -1000000
Buyback yield (%): 0
Retained earnings: -6926666.666666666
Receivables turnover: 3.846461949265688
Capitalized R&D asset: 1352222.2222222222
ROCI (R&D-adjusted, %): 12.161939119568038
FCF margin (%): -10.413051023950016
Rule of 40 score: -10.413051023950016
Financial ratios for IXI.L — annual report dated 2023-09-30
Total revenue: 8128048.780487806
Gross profit: 3987804.878048781
Operating income: -1648780.487804878
Net income: -1436585.3658536586
Capital expenditures: 121951.21951219512
Operating cash flow: 368292.68292682926
Depreciation & amortization: 762195.1219512195
Net tangible assets: 6445121.951219512
Owner earnings: -796341.4634146342
Return on net tangible assets (%): -12.355723746452224
Buffett classification: The Gruesome
Stock price: 0.0023170731707317076
Shares outstanding: 218974282
Book value: 13941463.414634148
P/B ratio: 0.03639355631560532
Market cap (USD): 507379.4339024391
Debt to equity: 0.03385234429671099
Current ratio: 4.907103825136612
Quick ratio: 4.907103825136612
Interest coverage ratio: -46.62068965517241
COGS to revenue (%): 50.937734433608405
R&D to revenue (%): 13.87846961740435
SG&A to revenue (%): 54.988747186796694
Free cash flow (dilution-adjusted): -2089024.3902439023
Buyback yield (%): 0
Retained earnings: -8975609.75609756
Receivables turnover: 7.052910052910053
Capitalized R&D asset: 2034037.669376694
ROCI (R&D-adjusted, %): -8.260059066839752
Rosenberg metric: -1.3590596629055849
FCF margin (%): -25.70142535633908
Revenue growth (%): -15.36221332362577
Rule of 40 score: -41.06363867996485
Financial ratios for IXI.L — annual report dated 2024-09-30
Total revenue: 7688000
Gross profit: 3614666.6666666665
Operating income: -2802666.6666666665
Net income: -2668000
Capital expenditures: 45333.333333333336
Operating cash flow: -2309333.3333333335
Depreciation & amortization: 633333.3333333334
Net tangible assets: 4120000
Owner earnings: -2079999.9999999998
Return on net tangible assets (%): -50.48543689320388
Buffett classification: The Gruesome
Stock price: 0.0012
Shares outstanding: 218974282
Book value: 12618666.666666668
P/B ratio: 0.02082384338546069
Market cap (USD): 262769.1384
Debt to equity: 0.03317836010143702
Current ratio: 2.8538754764930117
Quick ratio: 2.8538754764930117
Interest coverage ratio: -84.07999999999998
COGS to revenue (%): 52.98300381547
R&D to revenue (%): 23.18765175164759
SG&A to revenue (%): 69.40686784599376
Free cash flow (dilution-adjusted): -2948000
Buyback yield (%): 0
Retained earnings: -12470666.666666666
Receivables turnover: 3.5287637698898413
Capitalized R&D asset: 2984692.6829268294
ROCI (R&D-adjusted, %): -15.445951516557473
Rosenberg metric: -0.33078198198198244
FCF margin (%): -38.34547346514048
Revenue growth (%): -5.413953488372101
Rule of 40 score: -43.75942695351258
Financial ratios for IXI.L — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 4120000
Buffett classification: The Gruesome
Stock price: 0.0012
Shares outstanding: 218974282
Book value: 12618666.666666668
P/B ratio: 0.02082384338546069
Market cap (USD): 262769.1384
Debt to equity: 0.03317836010143702
Current ratio: 2.8538754764930117
Quick ratio: 2.8538754764930117
Buyback yield (%): 0
Retained earnings: -12470666.666666666
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IXI.L — quarterly report dated 2025-03-31
Capital expenditures: 0
Net tangible assets: 7459740.2597402595
Buffett classification: The Gruesome
Stock price: 0.001038961038961039
Shares outstanding: 218974282
Book value: 15962337.662337663
P/B ratio: 0.014252658498088032
Market cap (USD): 227505.74753246753
Debt to equity: 0.022374094866162233
Current ratio: 4.284958871915394
Quick ratio: 4.284958871915394
Buyback yield (%): 0
Retained earnings: -13276623.376623377
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IXI.L — quarterly report dated 2025-09-30
Capital expenditures: 0
Net tangible assets: 6154054.054054054
Buffett classification: The Gruesome
Stock price: 0.0017567567567567566
Shares outstanding: 218974282
Book value: 15860810.81081081
P/B ratio: 0.0242537758030161
Market cap (USD): 384684.54945945943
Debt to equity: 0.015250915906960894
Current ratio: 3.0306271268838114
Quick ratio: 3.0306271268838114
Buyback yield (%): 0
Retained earnings: -14563513.513513513
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for IXI.L — annual report dated 2025-09-30
Total revenue: 8829729.72972973
Gross profit: 4301351.3513513515
Operating income: -3400000
Net income: -2231081.081081081
Capital expenditures: 68918.91891891892
Operating cash flow: -1360810.810810811
Depreciation & amortization: 555405.4054054054
Net tangible assets: 6154054.054054054
Owner earnings: -1744594.5945945946
Return on net tangible assets (%): -28.348704435660956
Buffett classification: The Gruesome
Stock price: 0.0017567567567567566
Shares outstanding: 218974282
Book value: 15860810.81081081
P/B ratio: 0.0242537758030161
Market cap (USD): 384684.54945945943
Debt to equity: 0.015250915906960894
Current ratio: 3.0306271268838114
Quick ratio: 3.0306271268838114
Interest coverage ratio: -157.25
COGS to revenue (%): 51.28558310376492
R&D to revenue (%): 20.324456688093047
SG&A to revenue (%): 63.65166819712273
Free cash flow (dilution-adjusted): -2843243.2432432435
Buyback yield (%): 0
Retained earnings: -14563513.513513513
Receivables turnover: 4.487637362637363
Capitalized R&D asset: 3361237.358822237
ROCI (R&D-adjusted, %): -16.459395825106903
Rosenberg metric: 0.38520083284481205
FCF margin (%): -32.200795837159475
Revenue growth (%): 14.85080293613073
Rule of 40 score: -17.349992901028745
Financial ratios for JBCHEPHARM.NS — annual report dated 2022-03-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 9.989450085718055
Shares outstanding: 160558706
Market cap (USD): 1603893179.41448
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JBCHEPHARM.NS — annual report dated 2023-03-31
Total revenue: 379598733.2521316
Gross profit: 235287235.07917175
Operating income: 71557710.10962242
Net income: 49939744.21437272
Capital expenditures: 8737235.079171743
Operating cash flow: 76201230.20706455
Depreciation & amortization: 13935066.991473813
Net tangible assets: 134057490.86479904
Owner earnings: 55137576.126674786
Return on net tangible assets (%): 41.12979869381761
Capex to operating income (%): 12.210054046987791
Buffett classification: The Great
Stock price: 11.68026796589525
P/E ratio: 37.55262947057026
Shares outstanding: 160558706
Book value: 302113544.4579781
P/B ratio: 6.207496303093568
Market cap (USD): 1875368710.3373935
Debt to equity: 0.2307923044154777
Current ratio: 2.75594720743628
Quick ratio: 1.979529417748386
Effective tax rate (%): 26.15611907514076
Interest coverage ratio: 16.591791778222117
COGS to revenue (%): 38.01685451808589
SG&A to revenue (%): 12.042003069078394
Free cash flow (dilution-adjusted): -25421230.20706456
Buyback yield (%): 0
Retained earnings: 258840609.01339832
Inventory turnover: 2.752242997015222
Receivables turnover: 5.412503773028499
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 19.58673828181456
FCF margin (%): -6.696869083116681
Rule of 40 score: -6.696869083116681
Financial ratios for JBCHEPHARM.NS — annual report dated 2024-03-31
Total revenue: 413439381.2207699
Gross profit: 269183607.14713997
Operating income: 90254826.71783188
Net income: 66270272.21489387
Capital expenditures: 15096078.666506775
Operating cash flow: 96008118.47943398
Depreciation & amortization: 16587168.725266818
Net tangible assets: 177169384.81832355
Owner earnings: 67761362.27365392
Return on net tangible assets (%): 38.24665437718773
Capex to operating income (%): 16.72606243398194
Buffett classification: The Great
Stock price: 19.344769673704413
P/E ratio: 46.86824246935828
Shares outstanding: 160558706
Book value: 350561134.42858857
P/B ratio: 8.859998675382904
Market cap (USD): 3105971186.678023
Debt to equity: 0.12918691712220037
Current ratio: 2.134634399956417
Quick ratio: 1.5558533658456017
Effective tax rate (%): 26.46426683798415
Interest coverage ratio: 17.24174663645798
COGS to revenue (%): 34.89163844229917
SG&A to revenue (%): 12.05189822346738
Free cash flow (dilution-adjusted): 59632833.67310229
Buyback yield (%): 0
Retained earnings: 302281052.88403887
Inventory turnover: 2.3938671810946905
Receivables turnover: 5.019037184598821
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 24.07737801037205
FCF margin (%): 14.423597843297692
Revenue growth (%): 8.91484744396161
Rule of 40 score: 23.338445287259304
Financial ratios for JBCHEPHARM.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 214574773.05303392
Buffett classification: The Gruesome
Stock price: 21.95903010033445
Shares outstanding: 160558706
Book value: 383687290.96989965
P/B ratio: 9.18902851593628
Market cap (USD): 3525713457.9247494
Debt to equity: 0.031196396272994153
Current ratio: 3.076440699768459
Quick ratio: 2.2022607409313095
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for JBCHEPHARM.NS — annual report dated 2025-03-31
Total revenue: 451489630.5821837
Gross profit: 294800783.25929385
Operating income: 99897065.70025718
Net income: 77107996.25906008
Capital expenditures: 11278197.334580312
Operating cash flow: 105500327.33224222
Depreciation & amortization: 19994961.421557166
Net tangible assets: 240672843.11433247
Owner earnings: 85824760.34603693
Return on net tangible assets (%): 35.66034257768982
Capex to operating income (%): 11.289818430123596
Buffett classification: The Great
Stock price: 18.665421869529702
P/E ratio: 38.8662152787255
Shares outstanding: 160558706
Book value: 401369546.4110358
P/B ratio: 7.46667506071006
Market cap (USD): 2996895982.3157897
Debt to equity: 0.00812328585861519
Current ratio: 3.0406816532458607
Quick ratio: 2.2041758923337174
Effective tax rate (%): 25.671845440051495
Interest coverage ratio: 79.93933355785063
COGS to revenue (%): 34.704860689899746
SG&A to revenue (%): 12.068050109135262
Free cash flow (dilution-adjusted): 85017664.25064297
Buyback yield (%): 0
Retained earnings: 343128349.31026417
Inventory turnover: 2.5338935066913972
Receivables turnover: 4.736500752778953
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 23.466523756189346
FCF margin (%): 18.830479925090412
Revenue growth (%): 9.203344211928284
Rule of 40 score: 28.033824137018698
Financial ratios for JBCHEPHARM.NS — quarterly report dated 2025-03-31
Total revenue: 110998363.33878887
Gross profit: 73397241.05681552
Operating income: 21042787.000233807
Net income: 17031797.989244796
Capital expenditures: 0
Depreciation & amortization: 5429039.046060322
Net tangible assets: 240672843.11433247
Owner earnings: 22460837.03530512
Return on net tangible assets (%): 9.332518261993947
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 18.665421869529702
P/E ratio: 43.9897182935158
Shares outstanding: 160558706
Book value: 401369546.4110358
P/B ratio: 7.46667506071006
Market cap (USD): 2996895982.3157897
Debt to equity: 0.00812328585861519
Current ratio: 3.0406816532458607
Quick ratio: 2.2041758923337174
Effective tax rate (%): 24.524685282080505
Interest coverage ratio: 124.13793103448276
COGS to revenue (%): 33.8753844209462
Buyback yield (%): 0
Retained earnings: 343128349.31026417
Inventory turnover: 0.608066503918195
Receivables turnover: 1.1644649088251988
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.943098754462691
Rule of 40 score: 0
Financial ratios for JBCHEPHARM.NS — quarterly report dated 2025-06-30
Total revenue: 128006084.71799673
Gross profit: 87390592.08986661
Operating income: 30209454.71565645
Net income: 23681254.38801779
Capital expenditures: 0
Depreciation & amortization: 4996489.585771121
Owner earnings: 28677743.97378891
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 19.362508776035575
P/E ratio: 32.81941174922424
Shares outstanding: 160558706
Market cap (USD): 3108819353.993916
Effective tax rate (%): 25.488752255071606
Interest coverage ratio: 232.58558558558556
COGS to revenue (%): 31.72934530230177
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): 15.322497438360374
Rule of 40 score: 15.322497438360374
Financial ratios for JBCHEPHARM.NS — quarterly report dated 2025-09-30
Total revenue: 122311161.21758737
Gross profit: 83360766.6290868
Operating income: 29894024.80270575
Net income: 23429537.76775648
Capital expenditures: 0
Depreciation & amortization: 5010146.561443066
Net tangible assets: 279052987.5986471
Owner earnings: 28439684.329199545
Return on net tangible assets (%): 10.191499676793793
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 19.066967305524237
P/E ratio: 47.72753315695353
Shares outstanding: 160558706
Book value: 429057497.1815107
P/B ratio: 7.135098717606562
Market cap (USD): 3061367597.919278
Debt to equity: 0.010749551992516567
Current ratio: 3.7900381209487226
Quick ratio: 2.9347938947149834
Effective tax rate (%): 25.552570302704638
Interest coverage ratio: 196.41481481481483
COGS to revenue (%): 31.84533136694626
Buyback yield (%): 0
Inventory turnover: 0.5992056609663879
Receivables turnover: 1.1569428300257003
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 6.56624313127286
Revenue growth (%): -4.44894749570346
Rule of 40 score: -4.44894749570346
Financial ratios for JBCHEPHARM.NS — quarterly report dated 2025-12-31
Total revenue: 118605324.71872564
Gross profit: 81908209.86966693
Operating income: 27901303.3307341
Net income: 22044112.73253871
Capital expenditures: 0
Depreciation & amortization: 5051799.041996213
Owner earnings: 27095911.774534926
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 20.051910437785452
P/E ratio: 37.355052290288455
Shares outstanding: 160558706
Market cap (USD): 3219508792.7187257
Effective tax rate (%): 25.84779105931727
Interest coverage ratio: 133.2287234042553
COGS to revenue (%): 30.940528965361786
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -3.0298432800169186
Rule of 40 score: -3.0298432800169186
Financial ratios for KC — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 15.75
Shares outstanding: 299369665
Market cap (USD): 4715072223.75
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for KC — annual report dated 2022-12-31
Total revenue: 1175302729.8850574
Gross profit: 61715229.88505747
Operating income: -320173419.54022986
Net income: -381922988.50574714
Capital expenditures: 198850431.03448275
Operating cash flow: 27151436.781609196
Depreciation & amortization: 166296551.72413793
Net tangible assets: 457941954.0229885
Owner earnings: -414476867.81609195
Return on net tangible assets (%): -90.50860358500488
Buffett classification: The Gruesome
Stock price: 3.83
Shares outstanding: 299369665
Book value: 1376939511.4942527
P/B ratio: 0.8327060174965325
Market cap (USD): 1146585816.95
Debt to equity: 0.14087725161759815
Current ratio: 1.3588919095320866
Quick ratio: 1.3588919095320866
Interest coverage ratio: -16.169905378341507
COGS to revenue (%): 94.74899289214676
R&D to revenue (%): 11.872900929046528
SG&A to revenue (%): 14.8417374002565
Free cash flow (dilution-adjusted): -231073132.18390805
Buyback yield (%): 2.6112632059989997
Retained earnings: -1455694827.586207
Receivables turnover: 2.48187225382
Capitalized R&D asset: 139542528.73563218
ROCI (R&D-adjusted, %): -13.59492649054162
FCF margin (%): -19.660733044201013
Rule of 40 score: -19.660733044201013
Financial ratios for KC — annual report dated 2023-12-31
Total revenue: 991204078.7623066
Gross profit: 119573699.01547116
Operating income: -190508860.75949365
Net income: -306095639.9437412
Capital expenditures: 273762165.9634318
Operating cash flow: -23779184.24753868
Depreciation & amortization: 132275949.3670886
Net tangible assets: 203931082.9817159
Owner earnings: -447581856.54008436
Return on net tangible assets (%): -219.47701644884305
Buffett classification: The Gruesome
Stock price: 3.78
Shares outstanding: 299369665
Book value: 1019114486.6385372
P/B ratio: 1.1103927463856822
Market cap (USD): 1131617333.7
Debt to equity: 0.23771637051774355
Current ratio: 0.8930282825590642
Quick ratio: 0.8930282825590642
Interest coverage ratio: -9.275868680919837
COGS to revenue (%): 87.93652068454156
R&D to revenue (%): 11.136024732878976
SG&A to revenue (%): 12.255860656767025
Free cash flow (dilution-adjusted): -325661462.7285513
Buyback yield (%): 0
Retained earnings: -1732073277.0745428
Receivables turnover: 2.809445769722638
Capitalized R&D asset: 203874225.61714923
ROCI (R&D-adjusted, %): -11.990517999214227
Rosenberg metric: 0.41462964484489473
FCF margin (%): -32.855137474332956
Revenue growth (%): -15.663934613744615
Rule of 40 score: -48.51907208807757
Financial ratios for KC — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 2.94
Shares outstanding: 299369665
Market cap (USD): 880146815.1
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for KC — annual report dated 2024-12-31
Total revenue: 1066463013.6986302
Gross profit: 183688493.15068492
Operating income: -113105205.47945206
Net income: -269408219.1780822
Capital expenditures: 502987123.28767127
Operating cash flow: 86084794.52054794
Depreciation & amortization: 173026027.39726028
Net tangible assets: -18159452.05479452
Owner earnings: -599369315.0684932
Buffett classification: The Gruesome
Stock price: 10.49
Shares outstanding: 299369665
Book value: 754153424.6575344
P/B ratio: 4.164123218396933
Market cap (USD): 3140387785.85
Debt to equity: 0.9436913748882897
Current ratio: 0.7468567657284537
Quick ratio: 0.7468567657284537
Interest coverage ratio: -3.594471169543545
COGS to revenue (%): 82.77591526464386
R&D to revenue (%): 10.866659473512494
SG&A to revenue (%): 10.970317963104256
Free cash flow (dilution-adjusted): -447837123.28767127
Buyback yield (%): 0
Retained earnings: -1957802328.7671232
Receivables turnover: 2.9608469842274365
Capitalized R&D asset: 235893028.60641235
ROCI (R&D-adjusted, %): -8.565253946667553
Rosenberg metric: 0.5808513256142847
FCF margin (%): -41.99274775920402
Revenue growth (%): 7.592678092113757
Rule of 40 score: -34.400069667090264
Financial ratios for KC — quarterly report dated 2024-12-31
Total revenue: 305772876.7123288
Gross profit: 58352328.76712329
Operating income: -6834657.534246575
Net income: -26980684.93150685
Capital expenditures: 0
Operating cash flow: 78112602.73972602
Net tangible assets: -18159452.05479452
Owner earnings: -26980684.93150685
Buffett classification: The Gruesome
Stock price: 10.49
Shares outstanding: 299369665
Book value: 754153424.6575344
P/B ratio: 4.164123218396933
Market cap (USD): 3140387785.85
Debt to equity: 0.9436913748882897
Current ratio: 0.7468567657284537
Quick ratio: 0.7468567657284537
Interest coverage ratio: -0.807055854806619
COGS to revenue (%): 80.91644707191567
R&D to revenue (%): 7.8021469960244465
SG&A to revenue (%): 6.3592280419435685
Free cash flow (dilution-adjusted): -426433835.6164384
Buyback yield (%): 0
Retained earnings: -1957802328.7671232
Receivables turnover: 0.8489246117710058
Capitalized R&D asset: 23856849.315068495
ROCI (R&D-adjusted, %): 0.769228028587271
FCF margin (%): -139.46097515301446
Rule of 40 score: -139.46097515301446
Financial ratios for KC — quarterly report dated 2025-03-31
Total revenue: 271346694.21487606
Gross profit: 43843801.65289256
Operating income: -32259090.90909091
Net income: -43240495.86776859
Capital expenditures: 0
Operating cash flow: -57629476.58402204
Net tangible assets: -35411157.02479339
Owner earnings: -43240495.86776859
Buffett classification: The Gruesome
Stock price: 14.36
Shares outstanding: 299369665
Book value: 736176997.2451792
P/B ratio: 5.83955815719173
Market cap (USD): 4298948389.4
Debt to equity: 0.8709150935188399
Current ratio: 0.7285571936598699
Quick ratio: 0.7285571936598699
Interest coverage ratio: -2.825204772187172
COGS to revenue (%): 83.84214638038921
R&D to revenue (%): 11.480844700217311
SG&A to revenue (%): 16.565523353825956
Free cash flow (dilution-adjusted): -57629476.58402204
Buyback yield (%): 0
Retained earnings: -2011829614.325069
Receivables turnover: 0.8083989942906669
Capitalized R&D asset: 47136981.60307936
ROCI (R&D-adjusted, %): -1.375045783730911
Rosenberg metric: -0.6081493378535461
FCF margin (%): -21.238319026059692
Revenue growth (%): -11.258743047324273
Rule of 40 score: -32.497062073383965
Financial ratios for KC — quarterly report dated 2025-06-30
Total revenue: 327646722.4546723
Gross profit: 47260390.51603905
Operating income: -45604881.45048814
Net income: -63718688.9818689
Capital expenditures: 0
Operating cash flow: 203644909.34449095
Net tangible assets: 209192050.20920503
Owner earnings: -63718688.9818689
Return on net tangible assets (%): -30.459421817486014
Buffett classification: The Gruesome
Stock price: 12.52
Shares outstanding: 299369665
Book value: 984600557.8800559
P/B ratio: 3.806729719786117
Market cap (USD): 3748108205.7999997
Debt to equity: 0.7969152865337994
Current ratio: 0.9601985142035968
Quick ratio: 0.9601985142035968
Interest coverage ratio: -2.6228412837192887
COGS to revenue (%): 85.57580855319642
R&D to revenue (%): 8.270167165625118
SG&A to revenue (%): 20.072943142574132
Free cash flow (dilution-adjusted): 203644909.34449095
Buyback yield (%): 0
Retained earnings: -2100885355.6485355
Receivables turnover: 0.9015823563297132
Capitalized R&D asset: 55842129.950194694
ROCI (R&D-adjusted, %): -2.282138676112428
Rosenberg metric: 0.10967164144866041
FCF margin (%): 62.153806337148346
Revenue growth (%): 20.748374474469525
Rule of 40 score: 82.90218081161787
Financial ratios for KC — quarterly report dated 2025-09-30
Total revenue: 348037640.4494382
Gross profit: 53496488.76404494
Operating income: -20403792.134831462
Net income: -648876.404494382
Capital expenditures: 0
Operating cash flow: 241103651.68539324
Net tangible assets: 219385112.35955057
Owner earnings: -648876.404494382
Return on net tangible assets (%): -0.2957704821058858
Buffett classification: The Gruesome
Stock price: 14.92
Shares outstanding: 299369665
Book value: 993662078.6516852
P/B ratio: 4.495084896326918
Market cap (USD): 4466595401.8
Debt to equity: 0.8883920759578193
Current ratio: 0.9346954848847113
Quick ratio: 0.9346954848847113
Interest coverage ratio: -1.0598831228523278
COGS to revenue (%): 84.62910830708935
R&D to revenue (%): 8.056567560979941
SG&A to revenue (%): 13.17684868774687
Free cash flow (dilution-adjusted): 241103651.68539324
Buyback yield (%): 0
Retained earnings: -2116287640.449438
Receivables turnover: 0.8177317078321842
Capitalized R&D asset: 56475286.397898406
ROCI (R&D-adjusted, %): -0.9546370253752681
Rosenberg metric: 0.23014038365392195
FCF margin (%): 69.27516557520738
Revenue growth (%): 6.223446351607221
Rule of 40 score: 75.4986119268146
Financial ratios for KC — annual report dated 2025-12-31
Total revenue: 1365517000
Gross profit: 214772571.42857143
Operating income: -75338714.28571428
Net income: -133750142.85714285
Capital expenditures: 661010142.8571428
Operating cash flow: 543004000
Depreciation & amortization: 354337714.28571427
Net tangible assets: 596933285.7142857
Owner earnings: -440422571.4285714
Return on net tangible assets (%): -73.78086998475301
Buffett classification: The Gruesome
Stock price: 10.34
Shares outstanding: 299369665
Book value: 1330433428.5714283
P/B ratio: 2.3266720976966266
Market cap (USD): 3095482336.1
Debt to equity: 1.104331198619054
Current ratio: 1.170047394511866
Quick ratio: 1.170047394511866
Interest coverage ratio: -1.0588758513235672
COGS to revenue (%): 84.27170284745108
R&D to revenue (%): 8.47716600065344
SG&A to revenue (%): 11.681279481900052
Free cash flow (dilution-adjusted): -198320857.14285716
Buyback yield (%): 0
Retained earnings: -2178266857.142857
Receivables turnover: 3.041391491273509
Capitalized R&D asset: 229828349.96077847
ROCI (R&D-adjusted, %): -2.72317593838154
Rosenberg metric: 0.26822307551111363
FCF margin (%): -14.523499681282411
Revenue growth (%): 28.041665061051884
Rule of 40 score: 13.518165379769473
Financial ratios for KC — quarterly report dated 2025-12-31
Total revenue: 394483857.14285713
Gross profit: 66478571.428571425
Operating income: 25584571.42857143
Net income: -22891428.57142857
Capital expenditures: 0
Operating cash flow: 148946571.42857143
Net tangible assets: 596933285.7142857
Owner earnings: -22891428.57142857
Return on net tangible assets (%): -3.834838686208772
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 10.34
Shares outstanding: 299369665
Book value: 1330433428.5714283
P/B ratio: 2.3266720976966266
Market cap (USD): 3095482336.1
Debt to equity: 1.104331198619054
Current ratio: 1.170047394511866
Quick ratio: 1.170047394511866
Interest coverage ratio: 1.1673695531727668
COGS to revenue (%): 83.14796151354375
R&D to revenue (%): 6.887879170865946
SG&A to revenue (%): 12.97677580143602
Free cash flow (dilution-adjusted): -528534142.85714287
Buyback yield (%): 0
Retained earnings: -2178266857.142857
Receivables turnover: 0.8786268106212081
Capitalized R&D asset: 54900283.59537129
ROCI (R&D-adjusted, %): 1.00180090323836
Rosenberg metric: 0.4629862583970897
FCF margin (%): -133.981184093356
Revenue growth (%): 13.345170549208593
Rule of 40 score: -120.63601354414742
Financial ratios for KRITIKA.NS — annual report dated 2022-03-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 0.032045364631412374
Shares outstanding: 266280000
Market cap (USD): 8533039.694052488
Buyback yield (%): 0
Retained earnings: 3508044.3096399843
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for KRITIKA.NS — annual report dated 2023-03-31
Total revenue: 33580633.37393423
Gross profit: 1607259.4397076736
Operating income: 939951.2789281365
Net income: 729086.4799025579
Capital expenditures: 383995.12789281365
Operating cash flow: -562119.3666260658
Depreciation & amortization: 269269.18392204633
Net tangible assets: 9019512.789281365
Owner earnings: 614360.5359317906
Return on net tangible assets (%): 6.811460333665541
Capex to operating income (%): 40.85266295192432
Buffett classification: The Good
Stock price: 0.03313032886723508
P/E ratio: 12.099996658759062
Shares outstanding: 266280000
Book value: 9019512.789281365
P/B ratio: 0.9780954001474677
Market cap (USD): 8821943.970767358
Debt to equity: 0.29724295140323725
Current ratio: 2.0919381243365196
Quick ratio: 1.0853680064032654
Effective tax rate (%): 23.25700658991256
Interest coverage ratio: 3.306624389407833
COGS to revenue (%): 95.21373101629686
SG&A to revenue (%): 1.0719013989996262
Free cash flow (dilution-adjusted): -946114.4945188795
Buyback yield (%): 0
Retained earnings: 3857856.2728380025
Inventory turnover: 6.30624903905289
Receivables turnover: 7.668666605472434
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 10.027690824344534
FCF margin (%): -2.817440886190274
Rule of 40 score: -2.817440886190274
Financial ratios for KRITIKA.NS — annual report dated 2024-03-31
Total revenue: 50727533.277371384
Gross profit: 2344513.730663149
Operating income: 1419990.406523564
Net income: 1247247.8714474158
Capital expenditures: 1049514.3302554262
Operating cash flow: 1665235.63976496
Depreciation & amortization: 249394.41179997602
Net tangible assets: 10113550.785465883
Owner earnings: 447127.95299196546
Return on net tangible assets (%): 4.421077843743367
Capex to operating income (%): 73.90995921055965
Buffett classification: The Good
Stock price: 0.20093570057581575
P/E ratio: 42.898576597477884
Shares outstanding: 266280000
Book value: 10113550.785465885
P/B ratio: 5.2904424454188845
Market cap (USD): 53505158.34932822
Debt to equity: 0.475385033123105
Current ratio: 1.8553999049260204
Quick ratio: 1.2047373581317964
Effective tax rate (%): 24.71753150401355
Interest coverage ratio: 4.253034983119028
COGS to revenue (%): 95.37822247763624
SG&A to revenue (%): 0.9280480283411845
Free cash flow (dilution-adjusted): 499280.48926729825
Buyback yield (%): 0
Retained earnings: 3709185.7536874926
Inventory turnover: 9.211552511415526
Receivables turnover: 10.07768560782931
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 13.895287503476371
FCF margin (%): 0.9842396367615573
Revenue growth (%): 51.06187162254903
Rule of 40 score: 52.046111259310585
Financial ratios for KRITIKA.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 10617809.364548495
Buffett classification: The Gruesome
Stock price: 0.2230052556139513
Shares outstanding: 266280000
Book value: 10617809.364548497
P/B ratio: 5.592663931521627
Market cap (USD): 59381839.46488295
Debt to equity: 0.5571168706400891
Current ratio: 1.6098590292092474
Quick ratio: 1.0985082961237704
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for KRITIKA.NS — quarterly report dated 2025-03-31
Total revenue: 27957411.737198967
Gross profit: 1414414.30909516
Operating income: -122246.90203413607
Net income: 397194.2950666355
Capital expenditures: 0
Depreciation & amortization: 110158.98994622398
Net tangible assets: 11036240.355389291
Owner earnings: 507353.28501285944
Return on net tangible assets (%): 4.59715690013135
Buffett classification: The Gruesome
Stock price: 0.10036176916793091
P/E ratio: 16.82069218136254
Shares outstanding: 266280000
Book value: 11036240.355389291
P/B ratio: 2.421506874937391
Market cap (USD): 26724331.894036643
Debt to equity: 0.5426623871869836
Current ratio: 1.7097268556380842
Quick ratio: 0.9492564017085612
Effective tax rate (%): 39.92503005870287
Interest coverage ratio: -0.55839162706253
COGS to revenue (%): 94.94082527241532
Buyback yield (%): 0
Retained earnings: 4792845.45241992
Inventory turnover: 3.5802513521610924
Receivables turnover: 6.629364639352442
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -1.0865996092938195
Rule of 40 score: 0
Financial ratios for KRITIKA.NS — annual report dated 2025-03-31
Total revenue: 86926548.98293196
Gross profit: 3506534.9544072947
Operating income: 870107.5520224456
Net income: 1184802.4316109421
Capital expenditures: 901870.4699555762
Operating cash flow: 785889.6422726209
Depreciation & amortization: 472609.305588029
Net tangible assets: 11036240.355389291
Owner earnings: 755541.267243395
Return on net tangible assets (%): 6.846002288038642
Capex to operating income (%): 103.65045882653266
Buffett classification: The Gruesome
Stock price: 0.10036176916793091
P/E ratio: 22.55593943852759
Shares outstanding: 266280000
Book value: 11036240.355389291
P/B ratio: 2.421506874937391
Market cap (USD): 26724331.894036643
Debt to equity: 0.5426623871869836
Current ratio: 1.7097268556380842
Quick ratio: 0.9492564017085612
Effective tax rate (%): 31.532724423066533
Interest coverage ratio: 1.6493595709790365
COGS to revenue (%): 95.96609436882649
SG&A to revenue (%): 0.7092811877622232
Free cash flow (dilution-adjusted): -892225.8592471358
Buyback yield (%): 0
Retained earnings: 4792845.45241992
Inventory turnover: 11.25210590220288
Receivables turnover: 20.612344070521704
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 7.734008063510537
FCF margin (%): -1.0264135292226135
Revenue growth (%): 71.35970027879965
Rule of 40 score: 70.33328674957704
Financial ratios for KRITIKA.NS — quarterly report dated 2025-06-30
Total revenue: 24205031.59372806
Gross profit: 1292277.0886964663
Operating income: 232728.7619939153
Net income: 161022.7006786801
Capital expenditures: 0
Depreciation & amortization: 120278.49286215774
Owner earnings: 281301.19354083785
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 0.11596068336063657
P/E ratio: 47.94046217571398
Shares outstanding: 266280000
Market cap (USD): 30878010.765270308
Effective tax rate (%): 25.68049254698639
Interest coverage ratio: 1.9883035089473158
COGS to revenue (%): 94.66112207417521
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -13.42177229689022
Rule of 40 score: -13.42177229689022
Financial ratios for KRITIKA.NS — quarterly report dated 2025-09-30
Total revenue: 20250913.190529875
Gross profit: 1847023.6753100338
Operating income: 449560.31567080045
Net income: 128117.24915445321
Capital expenditures: 0
Depreciation & amortization: 116448.70349492671
Net tangible assets: 10922119.503945885
Owner earnings: 244565.9526493799
Return on net tangible assets (%): 2.2391803400523536
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 0.09537767756482526
P/E ratio: 37.00408098632851
Shares outstanding: 266280000
Book value: 10922119.503945885
P/B ratio: 2.325296658106178
Market cap (USD): 25397167.98196167
Debt to equity: 0.3976168259027737
Current ratio: 1.9044263468060891
Quick ratio: 1.2722556818822044
Effective tax rate (%): 24.716793640278233
Interest coverage ratio: 3.1625029740661437
COGS to revenue (%): 90.87930673578822
Buyback yield (%): 0
Inventory turnover: 3.6370999006296425
Receivables turnover: 4.783739733469687
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.037908299503514
Revenue growth (%): -16.335935724301084
Rule of 40 score: -16.335935724301084
Financial ratios for KRITIKA.NS — quarterly report dated 2025-12-31
Total revenue: 17949682.52200067
Gross profit: 1356912.1087222903
Operating income: 200512.4206305002
Net income: 181586.27603876573
Capital expenditures: 0
Depreciation & amortization: 115283.50228361368
Owner earnings: 296869.7783223794
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 0.08198730088002674
P/E ratio: 25.153891343329143
Shares outstanding: 266280000
Market cap (USD): 21831578.47833352
Effective tax rate (%): 26.552221321077763
Interest coverage ratio: 1.8711018711018712
COGS to revenue (%): 92.44046736169766
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -11.363589616320864
Rule of 40 score: -11.363589616320864
Financial ratios for LUXR.V — quarterly report dated 2025-05-31
Total revenue: 0
Operating income: -19276.8115942029
Net income: -52721.739130434784
Capital expenditures: 0
Operating cash flow: 0
Net tangible assets: 2986877.5362318843
Owner earnings: -52721.739130434784
Return on net tangible assets (%): -1.7651121778814627
Buffett classification: The Gruesome
Stock price: 0.1449275362318841
Shares outstanding: 19248960
Book value: 2986877.5362318843
P/B ratio: 0.9339868521511123
Market cap (USD): 2789704.3478260874
Debt to equity: 0
Current ratio: 62.138421387225215
Quick ratio: 62.138421387225215
Free cash flow (dilution-adjusted): 0
Buyback yield (%): 0
Retained earnings: -52721.739130434784
Receivables turnover: 0
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -0.6453833932047208
Rule of 40 score: 0
Financial ratios for LUXR.V — quarterly report dated 2025-08-31
Total revenue: 0
Operating income: -34330.656934306564
Net income: 179032.84671532846
Capital expenditures: 0
Operating cash flow: -9110.948905109488
Net tangible assets: 3187712.4087591236
Owner earnings: 179032.84671532846
Return on net tangible assets (%): 5.616342497628898
Buffett classification: The Gruesome
Stock price: 0.18248175182481752
P/E ratio: 4.904943430842931
Shares outstanding: 19248960
Book value: 3187712.4087591236
P/B ratio: 1.1019136895643538
Market cap (USD): 3512583.9416058394
Debt to equity: 0
Current ratio: 33.4433969663221
Quick ratio: 33.4433969663221
Free cash flow (dilution-adjusted): -12191.240875912408
Buyback yield (%): 0
Retained earnings: 125926.27737226276
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -1.0769684504779529
Rule of 40 score: 0
Financial ratios for LUXR.V — quarterly report dated 2025-11-30
Total revenue: 0
Operating income: -3100
Net income: 558383.5714285715
Capital expenditures: 2206.4285714285716
Operating cash flow: -37277.857142857145
Net tangible assets: 3677787.8571428573
Owner earnings: 556177.142857143
Return on net tangible assets (%): 15.122599901377054
Buffett classification: The Gruesome
Stock price: 0.15714285714285717
P/E ratio: 4.417788927156371
Shares outstanding: 19248960
Book value: 3677787.8571428573
P/B ratio: 0.8224608620515866
Market cap (USD): 3024836.571428572
Debt to equity: 0
Current ratio: 204.29390925194167
Quick ratio: 204.29390925194167
Free cash flow (dilution-adjusted): -39484.28571428572
Buyback yield (%): 0
Retained earnings: 681611.4285714286
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -0.08210517673139292
Rule of 40 score: 0
Financial ratios for LUXR.V — annual report dated 2025-11-30
Total revenue: 0
Operating income: -55696.42857142857
Net income: 681611.4285714286
Capital expenditures: 5220.714285714286
Operating cash flow: -46193.571428571435
Depreciation & amortization: 97857.14285714287
Net tangible assets: 3677787.8571428573
Owner earnings: 774247.8571428572
Return on net tangible assets (%): 21.051998843248747
Buffett classification: The Gruesome
Stock price: 0.15714285714285717
P/E ratio: 4.4377726731610805
Shares outstanding: 19248960
Book value: 3677787.8571428573
P/B ratio: 0.8224608620515866
Market cap (USD): 3024836.571428572
Debt to equity: 0
Current ratio: 204.29390925194167
Quick ratio: 204.29390925194167
Effective tax rate (%): 12.554341052878518
Free cash flow (dilution-adjusted): -51414.28571428572
Buyback yield (%): 0
Retained earnings: 681611.4285714286
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -1.4751500358595304
Rule of 40 score: 0
Financial ratios for MAMO — quarterly report dated 2024-09-30
Capital expenditures: 82312
Buffett classification: The Gruesome
Stock price: 3.75
Shares outstanding: 41640950
Market cap (USD): 156153562.5
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for MAMO — annual report dated 2024-12-31
Total revenue: 109325742
Gross profit: 32459939
Operating income: 5822369
Net income: 1761909
Capital expenditures: 225875
Operating cash flow: 6672278
Depreciation & amortization: 171346
Net tangible assets: 21704320
Owner earnings: 1707380
Return on net tangible assets (%): 7.866544540441718
Capex to operating income (%): 3.879434642496894
Buffett classification: The Great
Stock price: 2.57
P/E ratio: 60.7393693431386
Shares outstanding: 41640950
Book value: 21704320
P/B ratio: 4.930688521916374
Market cap (USD): 107017241.5
Debt to equity: 0.6989368936690944
Current ratio: 1.6948447647516292
Quick ratio: 0.6358004068782575
Effective tax rate (%): 27.093430745733688
Interest coverage ratio: 59.01029726250925
COGS to revenue (%): 70.30896986731634
R&D to revenue (%): 0.3141922421162255
SG&A to revenue (%): 24.051130611123593
Free cash flow (dilution-adjusted): 6284402
Buyback yield (%): 0
Retained earnings: 15047874
Inventory turnover: 2.819869333172895
Receivables turnover: 22.044760288930085
Capitalized R&D asset: 343493
ROCI (R&D-adjusted, %): 20.51719731050464
FCF margin (%): 5.748327781758847
Revenue growth (%): -4.965163373098439
Rule of 40 score: 0.7831644086604079
Financial ratios for MAMO — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 2.57
Shares outstanding: 41640950
Market cap (USD): 107017241.5
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for MAMO — quarterly report dated 2025-03-31
Total revenue: 14901722
Gross profit: 4224650
Operating income: -2706110
Net income: -2088707
Capital expenditures: 0
Operating cash flow: -3339474
Depreciation & amortization: 43651
Net tangible assets: 19902033
Owner earnings: -2045056
Return on net tangible assets (%): -10.27561355164068
Buffett classification: The Gruesome
Stock price: 2.7
Shares outstanding: 41640950
Book value: 19902033
P/B ratio: 5.649200008863416
Market cap (USD): 112430565
Debt to equity: 0.5835823405578716
Current ratio: 1.7938937809832216
Quick ratio: 0.5474218800874127
Interest coverage ratio: -2482.669724770642
COGS to revenue (%): 71.64992072728239
R&D to revenue (%): 5.644958347766789
SG&A to revenue (%): 40.86483427888401
Free cash flow (dilution-adjusted): -3339474
Buyback yield (%): 0
Retained earnings: 12959167
Inventory turnover: 0.4378316828402631
Receivables turnover: 2.658346824222412
Capitalized R&D asset: 841196
ROCI (R&D-adjusted, %): -7.765183604865815
FCF margin (%): -22.409987248453568
Rule of 40 score: -22.409987248453568
Financial ratios for MAMO — quarterly report dated 2025-06-30
Total revenue: 18915918
Gross profit: 6866417
Operating income: 142077
Net income: 77679
Capital expenditures: 0
Operating cash flow: -1391821
Depreciation & amortization: 43883
Net tangible assets: 20157959
Owner earnings: 121562
Return on net tangible assets (%): 0.6030471636538203
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 2.22
P/E ratio: 297.5157668095625
Shares outstanding: 41640950
Book value: 20157959
P/B ratio: 4.585926035468175
Market cap (USD): 92442909.00000001
Debt to equity: 0.5495266162611007
Current ratio: 1.8189957451741008
Quick ratio: 0.6118880713227972
Effective tax rate (%): 26.002381519409383
Interest coverage ratio: 2.230268115032023
COGS to revenue (%): 63.70032371677653
R&D to revenue (%): 0.7652655292753966
SG&A to revenue (%): 34.78331318628046
Free cash flow (dilution-adjusted): -1391821
Buyback yield (%): 0
Retained earnings: 13036846
Inventory turnover: 0.5147085885482379
Receivables turnover: 2.3266688749370696
Capitalized R&D asset: 708358.3200000001
ROCI (R&D-adjusted, %): -0.15342542812705856
Rosenberg metric: 3.1404892557739217
FCF margin (%): -7.357935258547855
Revenue growth (%): 26.937799537529962
Rule of 40 score: 19.579864278982107
Financial ratios for MAMO — quarterly report dated 2025-09-30
Total revenue: 16990855
Gross profit: 7134254
Operating income: 1788705
Net income: 1526407
Capital expenditures: 65361
Operating cash flow: 633230
Depreciation & amortization: 48325
Net tangible assets: 21718643
Owner earnings: 1509371
Return on net tangible assets (%): 6.949656108809377
Capex to operating income (%): 3.6540961198185276
Buffett classification: The Great
Stock price: 2.35
P/E ratio: 16.027218248475016
Shares outstanding: 41640950
Book value: 21718643
P/B ratio: 4.505632902571308
Market cap (USD): 97856232.5
Debt to equity: 0.46638489338399275
Current ratio: 2.0705630741316368
Quick ratio: 0.5707374288011918
Effective tax rate (%): 21.198343438181457
COGS to revenue (%): 58.01121250225489
R&D to revenue (%): 4.6298435246489955
SG&A to revenue (%): 26.831486702699774
Free cash flow (dilution-adjusted): 226213
Buyback yield (%): 0
Retained earnings: 14563253
Inventory turnover: 0.3928109224109436
Receivables turnover: 3.1565825833033916
Capitalized R&D asset: 1161231.8699999999
ROCI (R&D-adjusted, %): 6.887859388503954
Rosenberg metric: 1.8502524921074628
FCF margin (%): 1.3313809104956755
Revenue growth (%): -10.176947267375551
Rule of 40 score: -8.845566356879875